FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165485716> ?p ?o ?g. }

• W3165485716 endingPage "737" @default.
• W3165485716 startingPage "730" @default.
• W3165485716 abstract "Salvage treatment for local recurrence after prior partial nephrectomy (PN) or local tumor ablation (LTA) for kidney cancer is, as of yet, poorly investigated.To classify the treatments and standardize the nomenclature of salvage robot-assisted renal surgery, to describe the surgical technique for each scenario, and to investigate complications, renal function, and oncologic outcomes.Sixty-seven patients underwent salvage robot-assisted renal surgery from October 2010 to December 2020 at nine tertiary referral centers.Salvage robot-assisted renal surgery classified according to treatment type as salvage robot-assisted partial or radical nephrectomy (sRAPN or sRARN) and according to previous primary treatment (PN or LTA).Postoperative complications, renal function, and oncologic outcomes were assessed.A total of 32 and 35 patients underwent salvage robotic surgery following PN and LTA, respectively. After prior PN, two patients underwent sRAPN, while ten underwent sRARN for a metachronous recurrence in the same kidney. No intra- or perioperative complication occurred. For local recurrence in the resection bed, six patients underwent sRAPN, while 14 underwent sRARN. For sRAPN, the intraoperative complication rate was 33%; there was no postoperative complication. For sRARN, there was no intraoperative complication and the postoperative complication rate was 7%. At 3 yr, the local recurrence-free rates were 64% and 82% for sRAPN and sRARN, respectively, while the 3-yr metastasis-free rates were 80% and 79%, respectively. At 33 mo, the median estimated glomerular filtration rates (eGFRs) were 57 and 45 ml/min/1.73 m2 for sRAPN and sRARN, respectively. After prior LTA, 35 patients underwent sRAPN and no patient underwent sRARN. There was no intraoperative complication; the overall postoperative complications rate was 20%. No local recurrence occurred. The 3-yr metastasis-free rate was 90%. At 43 mo, the median eGFR was 38 ml/min/1.73 m2. The main limitations are the relatively small population and the noncomparative design of the study.Salvage robot-assisted surgery has a safe complication profile in the hands of experienced surgeons at high-volume institutions, but the risk of local recurrence in this setting is non-negligible.Patients with local recurrence after partial nephrectomy or local tumor ablation should be aware that further treatment with robot-assisted surgery is not associated with a worrisome complication profile, but also that they are at risk of further recurrence." @default.
• W3165485716 created "2021-06-07" @default.
• W3165485716 creator A5002762658 @default.
• W3165485716 creator A5006746754 @default.
• W3165485716 creator A5009936232 @default.
• W3165485716 creator A5013888713 @default.
• W3165485716 creator A5017441443 @default.
• W3165485716 creator A5022182189 @default.
• W3165485716 creator A5023902058 @default.
• W3165485716 creator A5025223836 @default.
• W3165485716 creator A5025441151 @default.
• W3165485716 creator A5029356947 @default.
• W3165485716 creator A5030308398 @default.
• W3165485716 creator A5031548152 @default.
• W3165485716 creator A5031550729 @default.
• W3165485716 creator A5032183911 @default.
• W3165485716 creator A5032356135 @default.
• W3165485716 creator A5032426514 @default.
• W3165485716 creator A5034920748 @default.
• W3165485716 creator A5036048233 @default.
• W3165485716 creator A5038974730 @default.
• W3165485716 creator A5043362229 @default.
• W3165485716 creator A5051587468 @default.
• W3165485716 creator A5056481246 @default.
• W3165485716 creator A5057178151 @default.
• W3165485716 creator A5061266716 @default.
• W3165485716 creator A5061623935 @default.
• W3165485716 creator A5078086666 @default.
• W3165485716 creator A5089751334 @default.
• W3165485716 date "2021-12-01" @default.
• W3165485716 modified "2023-10-18" @default.
• W3165485716 title "Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes" @default.
• W3165485716 cites W1577157491 @default.
• W3165485716 cites W1588043341 @default.
• W3165485716 cites W1795522823 @default.
• W3165485716 cites W1808057191 @default.
• W3165485716 cites W1944019414 @default.
• W3165485716 cites W1980970376 @default.
• W3165485716 cites W2024934637 @default.
• W3165485716 cites W2120058413 @default.
• W3165485716 cites W2124484612 @default.
• W3165485716 cites W2155965977 @default.
• W3165485716 cites W2164754805 @default.
• W3165485716 cites W2523401995 @default.
• W3165485716 cites W2593325515 @default.
• W3165485716 cites W2803584705 @default.
• W3165485716 cites W2884540301 @default.
• W3165485716 cites W2889961136 @default.
• W3165485716 cites W2892199528 @default.
• W3165485716 cites W2937337044 @default.
• W3165485716 cites W2966640318 @default.
• W3165485716 cites W2989693274 @default.
• W3165485716 cites W2126258785 @default.
• W3165485716 doi "https://doi.org/10.1016/j.eururo.2021.04.003" @default.
• W3165485716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34088520" @default.
• W3165485716 hasPublicationYear "2021" @default.
• W3165485716 type Work @default.
• W3165485716 sameAs 3165485716 @default.
• W3165485716 citedByCount "11" @default.
• W3165485716 countsByYear W31654857162022 @default.
• W3165485716 countsByYear W31654857162023 @default.
• W3165485716 crossrefType "journal-article" @default.
• W3165485716 hasAuthorship W3165485716A5002762658 @default.
• W3165485716 hasAuthorship W3165485716A5006746754 @default.
• W3165485716 hasAuthorship W3165485716A5009936232 @default.
• W3165485716 hasAuthorship W3165485716A5013888713 @default.
• W3165485716 hasAuthorship W3165485716A5017441443 @default.
• W3165485716 hasAuthorship W3165485716A5022182189 @default.
• W3165485716 hasAuthorship W3165485716A5023902058 @default.
• W3165485716 hasAuthorship W3165485716A5025223836 @default.
• W3165485716 hasAuthorship W3165485716A5025441151 @default.
• W3165485716 hasAuthorship W3165485716A5029356947 @default.
• W3165485716 hasAuthorship W3165485716A5030308398 @default.
• W3165485716 hasAuthorship W3165485716A5031548152 @default.
• W3165485716 hasAuthorship W3165485716A5031550729 @default.
• W3165485716 hasAuthorship W3165485716A5032183911 @default.
• W3165485716 hasAuthorship W3165485716A5032356135 @default.
• W3165485716 hasAuthorship W3165485716A5032426514 @default.
• W3165485716 hasAuthorship W3165485716A5034920748 @default.
• W3165485716 hasAuthorship W3165485716A5036048233 @default.
• W3165485716 hasAuthorship W3165485716A5038974730 @default.
• W3165485716 hasAuthorship W3165485716A5043362229 @default.
• W3165485716 hasAuthorship W3165485716A5051587468 @default.
• W3165485716 hasAuthorship W3165485716A5056481246 @default.
• W3165485716 hasAuthorship W3165485716A5057178151 @default.
• W3165485716 hasAuthorship W3165485716A5061266716 @default.
• W3165485716 hasAuthorship W3165485716A5061623935 @default.
• W3165485716 hasAuthorship W3165485716A5078086666 @default.
• W3165485716 hasAuthorship W3165485716A5089751334 @default.
• W3165485716 hasConcept C126322002 @default.
• W3165485716 hasConcept C141071460 @default.
• W3165485716 hasConcept C159641895 @default.
• W3165485716 hasConcept C2777472916 @default.
• W3165485716 hasConcept C2780091579 @default.
• W3165485716 hasConcept C2780227381 @default.
• W3165485716 hasConcept C2781068499 @default.
• W3165485716 hasConcept C31174226 @default.
• W3165485716 hasConcept C71924100 @default.

• next